Podowart is formulated for use on thick skin such as the hands, feet, or genital area. Applying it to facial skin, which is more delicate, can increase the risk of irritation and ulceration. Discuss alternative treatments with a dermatologist if facial warts are present.
Most users notice a mild burning or itching sensation within the first few minutes, which typically subsides. Redness may appear, and over the next several days the treated tissue often becomes a blister or scab as the wart resolves.
Podophyllum resin is not part of standard prohibited-substance lists for sport governing bodies such as UKAD. However, athletes subject to strict testing should disclose any topical medication to their medical team to avoid inadvertent complications.
Cryotherapy uses liquid nitrogen to freeze wart tissue, while Podowart delivers a chemical cytotoxic effect. Both are effective for common warts, but Podowart may be preferred when patients cannot tolerate the pain associated with freezing or when lesions are in hard-to-reach areas. Choice of therapy should be individualized.
Yes, a single-patient prescription bottle is generally allowed in carry-on luggage. Ensure the bottle is clearly labelled, keep it in its original packaging, and carry a copy of the prescription or a letter from the prescriber to satisfy customs officers if asked.
The exact excipient list varies by manufacturer, but typical formulations contain ethanol, propylene glycol, and a buffering agent to maintain stability. These components aid skin penetration and preserve the resin. If you have known sensitivities, ask your pharmacist for the full ingredient list.
Allergic contact dermatitis is rare but possible. Symptoms include intense itching, swelling, and a rash that spreads beyond the application site. Discontinue use immediately and seek medical attention if these signs develop.
When applied as directed-typically a thin layer once daily-a 10 ml bottle can treat several small warts for up to four weeks. Larger or multiple lesions may require more frequent applications, which could shorten the duration of a single bottle.
Combining Podowart with other topical agents (e.g., salicylic acid) can increase irritation and is not recommended without specialist advice. Sequential therapy-completing one regimen before starting another-is generally safer.
Do not discard Podowart in household waste. Return any unused product to a pharmacy for appropriate disposal, or follow local guidelines for safe disposal of medicinal waste.
Podowart is a topical skin-care product that contains Podophyllum resin as its active component. Podophyllum resin is a plant-derived extract that includes the potent compound podophyllotoxin. In the United Kingdom, Podowart is supplied in a 10 ml bottle and is classified as a prescription-only medication for the treatment of certain skin lesions. The product is formulated for external use on the skin and is marketed under the brand name “Podowart”.
Podophyllum resin exerts its therapeutic effect by acting as a mitotic inhibitor. The key molecule, podophyllotoxin, binds to tubulin proteins within cells and prevents the assembly of microtubules. This blocks the mitotic spindle apparatus, halting cell division. When applied to a wart or other hyper-proliferative skin lesion, the drug selectively damages the rapidly dividing, virus-infected keratinocytes while sparing surrounding healthy tissue. Because the action is local, systemic absorption is minimal, which limits the risk of whole-body toxicity.
Podowart is primarily indicated for the treatment of external warts (verruca vulgaris) and, in some formulations, genital warts caused by human papillomavirus (HPV). The product is applied directly to the visible lesion(s) until the wart resolves. In clinical practice within the UK, it is often used for:
Some clinicians have reported using podophyllum-based preparations for molluscum contagiosum or flat warts when standard treatments have failed. These uses are not formally approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and should only be considered after a risk-benefit assessment by a qualified dermatologist.
Disclaimer: Off-label use of any medication requires supervision by a healthcare professional and individualized risk assessment.
If any of these conditions apply, discuss alternative therapies with a healthcare provider.
These reactions usually resolve without intervention. If discomfort becomes severe, patients should seek medical advice.
Black-box warning: Podowart should never be applied to broken skin, mucous membranes, or large surface areas. Over-use can lead to systemic absorption and serious toxicity.
Podophyllotoxin is metabolised in part by hepatic CYP3A4 enzymes. Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) could theoretically increase local tissue concentrations, although clinical data are limited. As a precaution:
Note: The 10 ml bottle is intended for single-patient use. Do not share the product with others.
Patients using Podowart should schedule a follow-up appointment with their dermatologist within two weeks of initiating therapy to assess response and tolerability. The clinician may:
This article provides educational information about Podowart and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
